botulism antitoxin heptavalent

Botulism antitoxin heptavalent is an equine-derived, heptavalent antitoxin biologic marketed as BAT for treatment of symptomatic botulism after documented or suspected exposure to botulinum neurotoxin serotypes A, B, C, D, E, F, or G in adults and pediatric patients. It is a sterile intravenous mixture of toxin-neutralizing immune globulin antibody fragments, including F(ab')2-related fragments, produced from plasma of horses immunized against the seven botulinum neurotoxin serotypes. The product binds and neutralizes circulating toxin before cellular uptake; its approval was supported under the FDA Animal Rule, with efficacy based on animal-model studies of botulism. ([fda.gov](https://www.fda.gov/media/85514/download))

Brand names

BAT

Other names

Botulism Antitoxin Heptavalent A B C D E F G Equineheptavalent equine-derived botulinum antitoxin